Related Experiment Video
Updated: Apr 12, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Refining the treatment of NSCLC according to histological and molecular subtypes
Anish Thomas1, Stephen V Liu2, Deepa S Subramaniam2
1Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, Building 10, 4-4553, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA.
Abstract:
In the past decade, the characterization of non-small-cell lung cancer (NSCLC) into subtypes based on genotype and histology has resulted in dramatic improvements in disease outcome in select patient subgroups. In particular, molecularly targeted agents that inhibit EGFR or ALK are approved for the treatment of NSCLC harbouring genetic alterations in the genes encoding these proteins. Although acquired resistance usually limits the duration of response to these therapies, a number of new agents have proven effective at tackling specific resistance mechanisms to first-generation inhibitors. Large initiatives are starting to address the role of biomarker-driven targeted therapy in squamous lung cancers, and in the adjuvant setting. Immunotherapy undeniably holds great promise and our understanding of subsets of NSCLC based on patterns of immune response is continuing to evolve. In addition, efforts are underway to identify rare genomic subsets through genomic screening, functional studies, and molecular characterization of exceptional responders. This Review provides an overview of the key developments in the treatment of NSCLC, and discusses potential strategies to further optimize therapy by targeting disease subtypes.
Insights
Recent advances in non-small-cell lung cancer (NSCLC) treatment leverage molecular subtyping for targeted therapies and immunotherapy. Ongoing research aims to overcome resistance and optimize treatments for diverse NSCLC subtypes.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Non-small-cell lung cancer (NSCLC) treatment has advanced through molecular subtyping.
- Targeted therapies for EGFR and ALK alterations have improved outcomes in specific NSCLC subgroups.
- Acquired resistance remains a challenge, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review key developments in NSCLC treatment.
- To discuss strategies for optimizing therapy by targeting disease subtypes.
- To highlight the evolving role of targeted agents and immunotherapy.
Main Methods:
- Review of recent literature on NSCLC treatment advancements.
- Analysis of molecular subtyping, targeted therapies, and immunotherapy.
- Exploration of resistance mechanisms and novel therapeutic approaches.
Main Results:
- Molecularly targeted agents for EGFR/ALK-positive NSCLC show efficacy but face resistance.
- Biomarker-driven therapy is expanding to squamous NSCLC and adjuvant settings.
- Immunotherapy shows promise, with ongoing research into immune response patterns.
Conclusions:
- Personalized medicine through molecular subtyping is transforming NSCLC treatment.
- Addressing resistance mechanisms and exploring immunotherapy are crucial for further progress.
- Identifying rare genomic subsets and exceptional responders may reveal new therapeutic targets.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019